Citius Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary

Citius Pharmaceuticals

13/08/2024 03:23

* Citius Pharmaceuticals Inc  CTXR.OQ  reported a quarterly
adjusted loss of 6 cents​​ per share for the quarter ended in
June, identical to the same quarter last year.  The lone analyst
forecast for the quarter was for a loss of 6 cents per share. 
    * Reported revenue was zero​; analysts expected zero. 
    * Citius Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 6 cents​.
    * The company reported a quarterly loss of $10.89 million.
    * Citius Pharmaceuticals Inc shares had risen by 33.6% this
quarter and gained 3.1% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 20%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Citius
Pharmaceuticals Inc is $4.00 
This summary was machine generated from LSEG data August 13 at
02:23 a.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2024      -0.06          -0.06          Met
 Mar. 31 2024      -0.06          -0.05          Beat
 Dec. 31 2023      0.13           -0.06          Missed
 Sep. 30 2023      -0.02          -0.08          Missed